Oligomerix Appoints Medical Director William Erhardt, MD, to Board of Directors
WHITE PLAINS, NY, – (COMMERCIAL THREAD) – Oligomerix, Inc., a private company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative diseases and Alzheimer’s disease, today announced the appointment of William Erhardt, MD, medical director of Oligomerix , to its board of directors.
“As Chief Medical Officer, Bill provided valuable insight into our oral small molecule tau self-association inhibitor program as we complete the candidate’s preclinical testing by the end of the year,” said Vic Micati, President of Oligomerix. “With Bill joining the company’s board of directors, he will play a pivotal role in driving our clinical development program with our Phase 1 trial scheduled to begin early next year. ”
With over 20 years of executive leadership experience in the biopharmaceutical industry, Dr Erhardt joined Oligomerix last year as Medical Director. Prior to joining Oligomerix, he was Senior Vice President, Head of Clinical Development & Operations at Pfizer, Inc., with responsibility for Pfizer’s clinical development operations globally and leading a team of over 2 000 Pfizer researchers. During his long tenure at Pfizer, Bill was responsible for overseeing several clinical development and medical affairs units in several therapeutic areas, including the Pfizer Phase I units.
“There is a critical unmet need for new approaches to the treatment of Alzheimer’s disease and other rare neurodegenerative disorders,” said Dr. Erhardt. “Given the recent approval of a new treatment for Alzheimer’s disease, we are excited about the potential of our small molecule inhibitor targeting tau self-association and the possibility of offering patients a new therapeutic option. ”
About the main Oligomérix program
Oligomerix’s lead candidate is a small-molecule oral inhibitor of tau self-association that targets the onset of the tau aggregation cascade, a process considered important in the development of Alzheimer’s disease and ‘other neurodegenerative disorders. Our lead compound, OLX-07010, has been shown to be effective in several animal models of neurodegeneration and, upon completion of its preclinical program in the coming months, will begin phase 1 clinical studies in early 2022.
About Oligomérix, Inc.
Oligomerix is an emerging biotechnology company focused on the development of disease-modifying therapies for neurodegenerative diseases characterized by an aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease.
With a focus on oral, small molecule tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which should be successful. add significantly to new high-cost treatment options like the targeted monoclonal antibody against beta-amyloid which was recently approved by the US FDA.
Oligomerix is headquartered at the Westchester Park Center in White Plains, New York, and has laboratory facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on Twitter and LinkedIn.
Oligomerix is looking for strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our new website at https://oligomerix.com/.